EligibleTrials

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Recruiting · NCT06176508 · Interventional (participants receive a specific treatment) · Lead sponsor: Hansoh BioMedical R&D Company

View the official record on ClinicalTrials.gov →
Psoriasis

Interventions studied

HS-10374HS-10374-matched placebo tabletsTofacitinib 5Mg Tab,Oral

What this trial is about

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.